The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review

J. A. Cramer, 1 Á. Benedict, 2 N. Muszbek, 2 A. Keskinaslan, 3 Z. M. Khan 4

SUMMARY

Objectives: To review studies of patient compliance/persistence with cardiovascular or antidiabetic medication published since the year 2000; to compare the methods used to measure compliance/persistence across studies; to compare reported compliance/persistence rates across therapeutic classes and to assess whether compliance/persistence correlates with clinical outcomes. Methods: English language papers published between January 2000 and November 2005 investigating patient compliance/persistence with cardiovascular or antidiabetic medication were identified through searches of the MEDLINE and EMBASE databases. Definitions and measurements of compliance/persistence were compared across therapeutic areas using contingency tables. Results: Of the 139 studies analysed, 32% focused on hypertension, 27% on diabetes and 13% on dyslipidaemia. The remainder covered coronary heart disease and cardiovascular disease (CVD) in general. The most frequently reported measure of compliance was the 12-month medication possession ratio (MPR). The overall mean MPR was 72%, and the MPR did not differ significantly between treatment classes (range: 67–76%). The average proportion of patients with an MPR of > 80% was 59% overall, 64% for antihypertensives, 58% for oral antidiabetics, 51% for lipid-lowering agents and 69% in studies of multiple treatments, again with no significant difference between treatment classes. The average 12-month persistence rate was 63% and was similar across therapeutic classes. Good compliance had a positive effect on outcome in 73% of the studies examining clinical outcomes. Conclusions: Non-compliance with cardiovascular and antidiabetic medication is a significant problem, with around 30% of days ‘on therapy’ not covered by medication and only 59% of patients taking medication for more than 80% of their days ‘on therapy’ in a year. Good compliance has a positive effect on clinical outcome, suggesting that the management of CVD may be improved by improving patient compliance.

Introduction

Hypertension, dyslipidaemia and diabetes are well-known risk factors for cardiovascular disease (CVD), which is a leading cause of death and disability worldwide (1–5). Large-scale clinical trials have shown that pharmacological treatment can reduce the morbidity and mortality associated with CVD and that long-term or lifelong treatment is often indicated (6–9).

According to the World Health Organization, non-compliance with long-term medication for conditions such as hypertension, dyslipidaemia and diabetes is a common problem that leads to compromised health benefits and serious economic consequences in terms of wasted time, money and uncured disease (10). In addition, a recent editorial referred to the overwhelming evidence for a decrease in morbidity and mortality with the use of antihypertensive therapy, and concluded that the greatest potential for improving control of hypertension lies in improving patient compliance (11).

Compliance with medication has become a topic of much research, and various interventions have been proposed to improve patient compliance. However, it has proved difficult to compare studies of compliance because of a lack of standard terminology and methodology. Two recent Cochrane reviews...
of interventions aimed at improving compliance with lipid-lowering and antihypertensive treatments found ‘substantial heterogeneity’ in the measures of compliance used and therefore did not attempt to combine specific studies (12,13).

A literature review of research into patient compliance with antihypertensive, lipid-lowering or oral antidiabetic medications was therefore performed to aid current understanding of the medical significance of patient compliance in the treatment of CVD. The aims of the study were to review original research papers measuring compliance and/or persistence with antihypertensives (AHTs), lipid-lowering therapies (LLTs) and oral antidiabetics (OADs) published between 2000 and 2005; to compare the methodology used within the studies to measure compliance/persistence; to compare the reported compliance/persistence rates at the study level across the three treatment areas and to assess whether compliance/persistence correlates with clinical outcomes.

Methods

Searches

Searches for relevant research reports were conducted using the MEDLINE and EMBASE databases. The search terms used were: cardiovascular, hypertens*, hyperlipid*, dyslipid*, blood pressure, diabet*, adherence, persistence and compliance. A manual search of the reference lists from retrieved papers was also performed to identify further relevant studies.

Selection criteria

Studies were deemed relevant if they were English language, human, original research studies published between January 2000 and November 2005; if they involved patients with CVD or diabetes; if they examined compliance and/or persistence with pharmaceutical interventions (even if the primary objective was not to measure compliance); and if they provided a numeric measure of compliance or persistence with an adequate description of the methodology used. Posters were included only if available. Trials of clinical efficacy were not included unless they specifically investigated compliance. As the objective of any clinical trial is to maintain compliance at the highest possible level and as it is necessary to adhere to a protocol, such studies were not considered to be relevant to this assessment of compliance because they would be biased and skewed towards high compliance. The search was restricted to the 5-year period 2000–2005 to capture recent studies.

Studies were excluded from analysis if the study design and methods for calculating compliance/persistence were not appropriately described; if no numeric value for compliance/persistence was reported; if they examined non-compliance with antiplatelets, aspirin, digoxin, insulin, non-pharmaceutical therapies or treatment guidelines; and if they were reviews of earlier research papers, letters to the editor, commentaries or conference abstracts.

Data extraction

Parameters extracted from the studies included study design, country of study, number of patients, mean age of patients (weighted averages for studies with multiple treatment arms), mean study length (median if mean not available or time-frame of data collection if mean and median not available), definition of compliance or persistence, unit of measure of compliance or persistence and type of funding. No limits were set on the number of patients or the study length. Studies supported by industry (such as pharmaceutical companies, managed care organisations and consultancies) were identified, but unrestricted grants from pharmaceutical companies were considered to be non-industry funded.

Patients were classified as having hypertension, diabetes, dyslipidaemia, CVD or coronary heart disease (CHD). Myocardial infarction (MI) and heart failure were included under CHD, while stroke/transient ischaemic attack and other unspecified cardiovascular conditions were classified under CVD. Treatments were divided into AHTs, OADs and LLTs. Studies examining two or three therapeutic classes were categorised as ‘multiple treatment’.

Compliance definitions, measurements and data sources

Two common measures of compliance are adherence (sometimes used as a synonym for compliance) and persistence. Adherence refers to the proportion of pills taken within a specific time interval and persistence refers to the continuing use (in time) of the prescribed therapy (14). To aid future research into compliance, the Medication Compliance and Persistence Special Interest Group (MCP SIG) of the International Society for Pharmacoeconomics and Outcomes Research has proposed standard international definitions of medication compliance (adherence) and persistence (Figure 1) (15).

A commonly used measure of compliance is the mean medication possession ratio (MPR). This is usually defined as the number of days of treatment dispensed divided by the number of days between prescription refills (excluding the last prescription) (16). For example, a patient who receives daily treatment and is prescribed 90 days of medication but does not refill the prescription for a further 10 days...
 Medication Compliance (Synonym: Adherence) is the extent to which a patient acts in accordance with the prescribed dosing regimen. The unit of measure is administered doses per defined period of time, reported as the proportion of prescribed doses taken in the prescribed time interval.

 Medication Persistence is the accumulation of time from initiation to discontinuation of therapy, measured by time metric.

Figure 1 Definitions of medication compliance and persistence proposed by the Issues and Methods Definitions Working Group of the Medication Compliance and Persistence Special Interest Group (15)

has an MPR of 90/100 or 90%. Another commonly used measure of compliance is the percentage of patients with an MPR of more than 80% over a certain period of time, although the rationale for this cut-off point is often not justified and it is not necessary to use categorical rather than continuous data. A commonly used measure of persistence is the percentage of patients who are persistent with treatment at 1 year.

For this review, definitions of compliance and persistence, and their method of measurement, were recorded. Data on the MPR or the percentage of patients with an MPR of more than 80% at 1 year were extracted and analysed numerically. The percentage of patients persisting with treatment after 1 year was also analysed. All measures were classified as either continuous (able to take on any value, such as MPR) or discrete (limited to specific values). One compliance rate was calculated for each study. In studies with multiple treatment arms, population-weighted averages were used.

The sources of prospectively collected compliance data in the studies were also identified and classified as either electronic monitoring using standard pill bottles fitted with microprocessors to record the time and frequency of bottle openings (Medication Event Monitoring System, MEMS); pill counts, comprising the number of pills left in a returned container; or questionnaires. Retrospectively collected data using pharmacy claims (de-identified data from administrative databases) were also noted. In studies with multiple data sources, the most sophisticated data source was recorded using the order MEMS > pill count > pharmacy claims data > questionnaire.

The relationship between compliance and patient outcome was investigated by recording clinical parameters (such as systolic or diastolic blood pressure, glycated haemoglobin levels and total blood cholesterol levels) and events (such as hospitalisations and emergency room visits). Cases were then classified according to the relationship between good compliance and persistence, and the change in outcome. For example, a positive relationship was taken as a positive change in outcome with good compliance, while a neutral relationship was taken as no change in outcome with good compliance.

Statistical analysis
Results were presented in contingency tables. Associations between categorical variables were assessed using the chi-squared test and Fisher’s exact test. Patient numbers and age, and study length, were compared using the t-test and Mann–Whitney test. The level of significance was taken as p < 0.05.

Results
Study characteristics
A total of 151 papers were identified from the literature search. A list of these papers is provided in the Appendix. From these papers, 139 studies which satisfied the inclusion criteria were identified, and were included in the analysis. Of the 139 studies, approximately one-third (31.6%) focused on hypertension, 27.3% on diabetes and 13.0% on dyslipidaemia. The remainder involved patients with CHD (17.3%) or CVD (10.8%). The majority of studies investigated one therapeutic class, and most were studies of AHTs (38.1%), followed by OADs (25.2%), LLTs (mostly statins; 23.0%) and multiple treatments (13.7%).

Compliance definitions, measurement and data sources
The definitions and measures of compliance varied considerably between studies. Definitions were often not compatible with the standard MCP SIG definitions (Figure 1). Eighty-eight studies (63%) examined compliance only, 18 (13%) persistence only and 33 (24%) examined both compliance and persistence. The studies measuring both compliance and persistence were mostly retrospective in design, and were more likely to focus on LLTs (41%) than AHTs (17%), OADs (23%) or multiple treatments (10%).
Of the 139 studies, 104 (75%) used a continuous measure for compliance and 57 of these applied at least one cut-off value. The most common cut-off value applied to the MPR was 80% (43 studies).

Analysis of the sources of compliance data showed that the largest number of studies used pharmacy claims data, followed by questionnaires, MEMS, ‘other’ sources and pill counts (Figure 2).

**Compliance**

The most frequently reported measure of compliance was the 12-month MPR. The overall mean MPR was 72% [standard deviation (SD) 0.18], showing that only 72% of days ‘on therapy’ were actually covered by medication. The mean 12-month MPR did not differ significantly between therapeutic classes (Table 1). The overall proportion of patients with an MPR of > 80% was 59% (SD 0.19), showing that only 59% of patients had medication for more than 80% of their days ‘on therapy’ in the year. The proportion of patients with an MPR above 80% at 12 months was highest for AHTs (64%), followed by OADs (58%) and LLTs (51%), but the differences between therapeutic classes were not significant.

**Persistence**

Many different measures of persistence were used over many different time frames. The 12-month persistence rate varied from 35.1% to 92.0% for the 22 estimates, with an average of 63.3% (SD 0.18). Persistence rates were similar for the different therapeutic classes (61.8% for AHTs, 62.3% for OADs and 65.6% for LLTs). There was a statistically significant trend towards decreased persistence with time (p < 0.001; Figure 3). The average persistence rate across the European studies was 61.7% over a mean observation period of 17 months. This compared with an average persistence rate of 51.1% in the US studies over a mean observation period of 21 months.

**Clinical outcomes**

Fifty of the 139 studies (36%) reported outcomes. These comprised clinical parameters (e.g. systolic or diastolic blood pressure, blood glycated haemoglobin or cholesterol levels) or events (e.g. hospitalisations or emergency room visits). Therapeutic class did not appear to affect the relationship between compliance and outcome, whereas study design did; prospective studies were more likely than retrospective studies to show a relationship (p = 0.0001; Table 2). Studies using MEMS as a source of data were also significantly more likely to link compliance and outcome than studies using pharmacy claims (p = 0.004; Table 2).

The relationship between compliance and outcome was investigated in 41 of the 50 studies reporting outcomes. In 30 studies (73%), the effect of good compliance on outcome was positive, and a positive

![Figure 2](source-of-compliance-data-over-time.png)
relationship was implied in a further three studies (7%). Only eight studies (20%) found good compliance to have a neutral or implied neutral effect on outcome.

Study trends
An analysis of study trends according to the year of publication showed that the proportion of retrospective studies increased significantly between 2000 and 2005 ($p = 0.002$ for trend; Table 3). The use of continuous measures of compliance also increased significantly, while the use of discrete measures decreased ($p = 0.009$ for trend). Discrete measures are used most often in cross-sectional surveys and questionnaires, suggesting that use of such data sources became less common over the 5-year period. The average number of patients in each study, the mean patient age, the average study length, the distribution of studies across therapeutic class, the country of study and the source of funding did not change between 2000 and 2005.

A comparison of retrospective and prospective studies showed that prospective studies were more likely to be European based, to involve fewer patients (mean 893 vs. 15,123 for retrospective studies; $p = 0.001$) and to be shorter in length (mean 12.5 months vs. 23.2 months for retrospective studies; $p = 0.001$) than retrospective studies. In addition, prospective studies were more likely to be funded by industry (54% funded by industry vs. 22% of retrospective studies; $p = 0.00008$).

### Table 1 Compliance results by therapeutic class, study design and data source

| Measure                                      | Therapeutic class (%) | Study design (%) | Data source (%) |
|----------------------------------------------|-----------------------|-----------------|-----------------|
|                                              | AHTs ($n = 53$)       | OADs ($n = 35$) | LLTs ($n = 32$) |
| Average 12-month MPR                         | 67 (12)               | 76 (10)         | 74 (8)          |
| Proportion of patients with MPR > 80% at 12 months | 64 (7)               | 58 (7)          | 51 (9)          |

Number of studies ($n$) are shown in parentheses. *Includes studies with multiple treatment arms. AHTs, antihypertensives; LLTs, lipid-lowering therapies; MEMS, medication event monitoring system; MPR, medication possession ratio; OADs, oral antidiabetics.

![Figure 3](image-url) Persistence rates from the different studies, showing a significant trend ($p < 0.001$) towards decreased persistence with time.
Therapeutic class

Patient numbers, the mean age of patients and the source of funding did not differ significantly between therapeutic classes. A higher proportion of LLT studies were retrospective (72%) compared with other therapeutic classes (40% for AHTs, 57% for OADs, 50% for multiple treatments), and there was a significant association between study design and therapeutic class \((p = 0.042)\). LLT studies also showed the longest study duration (mean 30.1 months vs. 15.3 months for AHTs, 18.0 months for OADs, 10.7 months for multiple treatments). The mean study duration was significantly different between therapeutic classes \((p = 0.001)\). Studies of multiple groups of treatments were shorter in duration than studies of a single group of medications (mean study duration 10.7 vs. 20.3 months respectively; \(p = 0.001)\).

Discussion

The results of this study confirm the view that compliance and persistence with cardiovascular medication is poor, regardless of the method used for data collection \((10,11)\). In terms of compliance, patients filled 72% of prescriptions in the first year of treatment. Thus, almost 30% of days ‘on therapy’ were not actually covered by medication. Furthermore, only 59% of patients had medication for more than 80% of their days ‘on therapy’ in the year. The results of one study with a follow-up of more than 2 years showed that compliance decreases at first but then reaches a plateau \((17)\).

Persistence also decreased with time, but with wide variability. The reasons for the variability in persistence rates are unclear. The 10% point difference between European and North-American persistence rates may have been due to differences in the average follow-up time between the different studies. However, other factors are clearly involved. In a study comparing compliance with statin therapy in Italy and Denmark, 91% of patients remained persistent after 2 years in Denmark, but only 48% remained persistent at this time in Italy \((18)\). No single explanation for the difference emerged from the study, although differences in prescribing practices between the two countries could have played a role.

This systematic review confirmed previous findings that the definitions and measures of compliance vary considerably between studies \((12,13)\). However, there were some encouraging signs of a move towards using standard methodology, especially in retrospective analyses of pharmacy claims, in which MPR was
the measure of choice in almost all cases. As studies move towards the use of a standard measure for compliance, it should become easier to compare estimates of compliance, enabling the influence of patient or regimen characteristics on compliance to be determined.

Many of the studies analysed in this review used the definition of MPR proposed by Steiner and Procaccia (16). It has been argued that it is more informative to report the percentage of patients above a certain threshold of MPR rather than mean MPR (19). However, the authors of this review believe that graphic presentation of the whole distribution as a histogram along with mean, SD or quintiles is preferable. Presenting compliance and persistence over time graphically is also very informative, as charted in 25 of the studies included in this review [see for example Sturkenboom et al. (20)].

The most important reason for investigating these issues is that poor compliance and lack of persistence with medications for hypertension, hyperlipidaemia and diabetes potentially lead to suboptimal health outcomes. Around one-third of studies in this review investigated the effect of compliance on outcomes, and the majority (73%) showed that compliance has a positive influence on outcome. Only one instance of a marginally negative effect of compliance on outcome (raised systolic blood pressure) was identified (21) and only a few studies found compliance to have a neutral effect on outcome (22–26). In addition, two of the studies reviewed (27,28) found mortality rates to be lower in more compliant patients.

A number of recent studies have shown that patients who are compliant with therapy are likely to have better outcomes. In a meta-analysis, which included cardiovascular studies, a consistent association between good adherence to drug therapy and reduced mortality was found (29). Similarly, increased compliance and persistence with long-term cardiovascular therapy have been shown to reduce the risk of adverse cardiovascular outcomes; compliant patients (MPR ≥ 80%) showing a reduced predicted relative risk of 4.6% for men and 16.4% for women (11). Another study showed that patients who were highly compliant with antihypertensive therapy were 45% more likely to achieve blood pressure control than those with medium or low compliance (odds ratio 1.45, p = 0.026) (30).

In another study investigating the relationship between persistence (defined as < 60 days gap between refills) with antihypertensive therapy and the risk of MI/stroke, multivariate analysis showed that persistent users were at significantly lower risk of MI/stroke than non-persistent patients (relative risk 0.88, 95% confidence interval: 0.82–0.94) (31). Better compliance with antihypertensive therapy has also been shown to reduce the risk of hospitalisation (32), while better compliance with antidiabetic medication has been shown to reduce emergency room visits by 26% over a 2- to 3-year period (33).

Over the 5-year period of the present study, a trend towards more retrospective studies using data collected from pharmacy claims databases was seen. This was not surprising given that such studies take less time and money than prospective studies and potentially provide larger numbers of patients.

One limitation of the present review is that one person selected the studies and extracted the data. Thus, relevant studies may have been missed or incorrectly categorised. Another limitation is that although study characteristics and compliance measures were examined at the study level, differences between treatment arms within studies (e.g. different classes of AHTs, different doses) were not investigated. In studies with multiple treatment arms, population-weighted averages were used to calculate compliance. Meta-analysis was beyond the scope of this review. Because of the number of papers included in the review, study characteristics were presented only in tabular form. In addition, only means and SDs of compliance measures were calculated, without multivariate analysis. Finally, semi-transparency of definitions in some papers made it difficult to determine whether methods, and consequently compliance measures, were truly comparable.

Prospective real-world studies that use standard definitions and measures of compliance, and focus on objective outcomes, such as mortality, are needed to further our understanding of the issue of compliance. Large retrospective studies that analyse existing databases, identify appropriate stratification subgroups and use modelling exercises would also be useful.

Conclusions

In this systematic review, poor compliance and persistence with cardiovascular and antidiabetic medication proved to be a significant problem, with almost 30% of days ‘on therapy’ not actually covered by medication and only 59% of patients having medication for more than 80% of their days ‘on therapy’ in the year. The definitions and measures of compliance/persistence used varied widely between studies making comparisons difficult. However, there were signs of a move towards the use of standard terminology and methodology. The most frequent measure of compliance was the 12-month MPR, which did not differ between therapeutic classes. Similarly, 12-month persistence rates did not differ between
therapeutic classes but did show a significant trend towards a decrease over time. The majority of studies investigating the relationship between compliance and outcome found that compliance had a positive effect on outcome, suggesting that the management of CVD may be improved by improving patient compliance.

Further research into the problem of poor compliance with cardiovascular and antidiabetic medication is warranted to increase the number of published studies in this area and to increase awareness of the problem. By increasing awareness, it may be possible to improve patient compliance. The availability of different targeted interventions, including behavioural training and electronic devices designed specifically to improve patient compliance, may also contribute to improved compliance and persistence, and hence to improved clinical outcomes.

Acknowledgement

Funding for this study was provided by Novartis Pharma AG.

References

1. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am J Heart 1991; 121: 1244–63.
2. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993; 270: 2207–12.
3. American Heart Association. Heart Disease and Stroke Statistics – 2006 Update. Dallas, TX: American Heart Association.
4. Michaud CM, McKenna MT, Begg S et al. The burden of disease and injury in the United States 1996. Popul Health Metr 2006; 4: 11.
5. Thom T, Haase N, Rosamond W et al. Heart disease and stroke statistics – 2006 update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. 2006; 113: e83–151, Epub 11 January 2006.
6. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995; 346: 1647–53.
7. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual BP to vascular mortality. Lancet 2002; 360: 1903–13.
8. Baigent C, Keech A, Kearney PM et al. The Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–78.
9. Cashman WC, Basile J. Achieving blood pressure goals: why aren’t we? J Clin Hypertens (Greenwich) 2006; 8: 865–72.
10. World Health Organization (WHO). Adherence to Long Term Therapies: Evidence for Action. Geneva: WHO; 2003.
11. Halpern MT, Khan ZM, Schmier JK et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006; 47: 1039–48.
12. Schellhauer A, Schroeder A, Peters TJ et al. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2004; CD004371.
13. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004; CD004804.
14. Berger ML, Bingefoes K, Hedblom EC et al. (eds). Healthcare Cost, Quality and Outcomes: ISPOR Book of Terms. Lawrenceville, NJ: ISPOR, 2003.
15. ISPOR Medication Compliance and Persistence Special Interest Group (MCP): Accomplishments. International Society for Pharmacoeconomics & Outcomes Research (ISPOR). http://www. ispor.org/sgs/mcp_accomplishments.asp#definition (accessed June 2007).
16. Steiner JE, Pochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50: 105–16.
17. Chapman RH, Benner JS, Pettlra AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165: 1147–52.
18. Larsen J, Vaccheri A, Andersen M et al. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 2000; 49: 463–71.
19. Wetzels GE, Nelemans P, Schouten JS et al. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22: 1849–55.
20. Sturkenboom MCJM, Picelli G, Dielemann JP et al. Patient adherence and persistence with antihypertensive therapy: one-versus two-pill combinations. J Hypertens 2005; 23 (Suppl. 2): S236.
21. Choo PW, Rand CS, Inui TS, Lee ML, Ma CC, Platt R. A pharmacodynamic assessment of the impact of antihypertensive non-adherence on blood pressure control. Pharmacopeiadiol Drug Saf 2000; 9: 557–63.
22. Bertholet N, Favrat B, Fallab-Stubi CL, Brunner HR, Burnier M. Why objective monitoring of compliance is important in the management of hypertension. J Clin Hypertens (Greenwich) 2000; 2: 258–62.
23. Blonde L, Wogen J, Krelick C et al. Greater reductions in A1C in type 2 diabetic patients new to therapy with glipuzide/metformin tablets as compared to glipuzide-co-administered with metformin. Diabetes Obes Metab 2003; 5: 424–31.
24. Hope CJ, Wu J, Tu W, Young J, Murray MD. Association of medication adherence, knowledge, and skills with emergency department visits by adults 50 years or older with congestive heart failure. Am J Health Syst Pharm 2004; 61: 2043–9.
25. Rosen MI, Rigby MO, Salahi JT et al. Electronic monitoring and counseling to improve medication adherence. Behav Res Ther 2004; 42: 409–22.
26. Charpentier G, Fleury F, Dubroca I. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. Diabetes Metab 2005; 31: 189–95.
27. Mulhestein JB, Horne BD, Bair TL et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001; 87: 257–61.
28. Howell N, Trotter R, Mottram DR et al. Compliance with statins in primary care. Pharm J 2004; 272: 23–6.
29. Simpson SH, Euirch DT, Majumdar SR et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15, Epub 21 June 2006.
30. Bramley T, Gerbino PP, Nightengale BS et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12: 239–45.
31. Breekveldt-Postma NS, Siiskonen SJ, Penning-Van Beest FJA et al. Non-persistent use of antihypertensive drugs leads to increased risk of hospitalizations for acute myocardial infarction or stroke. Abstract presented at: ISPOR; October, 2006. Value Health Suppl 2006; 9: A339.
32. Sokol MC, McGuigan KA, Verbrugge RR et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: S21–30.
33. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care 2005; 11: S170–6.
Appendix. Studies included in the systematic review

1. Abrahá I, Montedori A, Stracci F, Rossi M, Romagnoli C. Statin compliance in the Umbrian population. Eur J Clin Pharmacol 2003; 59: 659–61, Epub 24 September 2003.

2. Abogboso SM, Kogut SJ, Andrade SE, Larrat P, Gurwitz JH. Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients. J Manag Care Pharm 2004; 10: 404–11.

3. Akpý MR, Agomoulu DI, Odiá OJ. Drug compliance among hypertensive patients in Port Harcourt, Nigeria. Niger J Med 2005; 14: 55–7.

4. Andresják M, Genes N, Vaur L, Poncelet P, Clerson P, Carre A. Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen. Am J Hypertens 2000; 13: 184–90.

5. Artinian NT, Harden JK, Kronenberg MW, Vander Wal JS, Daher E. Pilot study of a web-based compliance monitoring device for patients with congestive heart failure. Heart Lang 2003; 32: 226–33.

6. Ashida T, Sugiyama T, Okuno S, Ebihara A, Fujii J. Relationship between home blood pressure measurement and medication compliance and name recognition of antihypertensive drugs. Hypertens Res 2000; 23: 21–4.

7. Balkrishnan R, Rajagopalan R, Shenolikar RA, Camacho FT, Whitmire JT, Anderson RT. Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis. Curr Med Res Opin 2004; 20: 1633–40.

8. Balkrishnan R, Rajagopalan R, Camacho FT et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003; 25: 2958–71.

9. Balkrishnan R, Rajagopalan R, Shenolikar RA et al. Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis. Curr Med Res Opin 2004; 20: 1633–40.

10. Bartels D. Adherence to oral therapy for type 2 diabetes: opportunities for enhancing glycemic control. J Am Acad Nurse Pract 2004; 16: 8–16.

11. Baune BT, Aljeesh YI, Bender R. The impact of non-compliance with the therapeutic regimen on the development of stroke among hypertensive men and women in Gaza, Palestine. Saudi Med J 2004; 25: 1683–8.

12. Bell DS. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy. Clin Ther 2004; 26: 1714–27.

13. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455–61.

14. Benner JS, Pollack MF, Smith TW, Bullano MF, Willey VI, Williams SA. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm 2005; 62: 1468–75.

15. Benner JS, Tierce JC, Ballantyne CM et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004; 22 (Suppl. 3): 1–33.

16. Bertholet N, Favrat B, Fallab-Stubi CL, Brunner HR, Burnier M. Why objective monitoring of compliance is important in the management of hypertension. J Clin Hypertens (Greenwich) 2000; 2: 258–62.

17. Bhagat K, Mazayi-Mupanemunda M. Compliance with medication in patients with heart failure in Zimbabwe. East Afr Med J 2001; 78: 45–8.

18. Bharucha NE, Kuruvilla T. Hypertension in the Parsi community of Bombay: a study on prevalence, awareness and compliance to treatment. BMC Public Health 2003; 3: 1.

19. Blonde L, Wogen J, Kreilk C et al. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003; 5: 424–31.

20. Bobb-Liverpool B, Duff EM, Bailey EY. Compliance and blood pressure control in women with hypertension. West Indian Med J 2002; 51: 236–40.

21. Bocuzzi SJ, Wogen J, Fox J et al. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care 2001; 24: 1411–5.

22. Bohachick P, Burke LE, Sereika S, Muriali S, Dunbar-Jacob J. Adherence to angiotensin-converting enzyme inhibitor therapy for heart failure. Prog Cardiovasc Nurs 2002; 17: 160–6.

23. Berghi C, Prandin MG, Dormi A, Ambrosioni E. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press Suppl 2003; 1: 14–21.

24. Boury ML, Hererdink ER, Urquhart J, Groobbe DE, Hoes AW, Leukens HG. Effect of a pharmacist-led intervention on diuretic compliance in heart failure patients: a randomized controlled study. J Card Fail 2003; 9: 404–11.

25. Bovet P, Burnier M, Madeleine G, Waerber B, Paccaud F. Monitoring one-year compliance to antihypertensive medication in the Seychelles. Bull World Health Organ 2002; 80: 35–9.

26. Burnier M, Schneider MP, Chiolelo A, Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001; 19: 335–41.

27. Butler I, Arboagat PG, BeLuer R et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol 2002; 40: 1589–95.

28. Catalan VS, LeLoirier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value in Health 2000; 3: 417–26.

29. Catalan VS, Couture JA, LeLoirier J. Predictors of persistence of use of the novel antioxidant agent acarbose. Arch Intern Med 2001; 161: 1106–12.

30. Chapman RH, Benner JS, Petrella AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165: 1147–52.

31. Charles H, Good CB, Hansu BH, Chang CC, Whittle J. Racial differences in adherence to cardiac medications. J Natl Med Assoc 2003; 95: 17–27.

32. Charpentier G, Fleury F, Dubroca I. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. Diabetes Metab 2005; 31: 189–95.

33. Cheng CW, Woo KS, Chan JC, Tomlinson B, You JH. Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. Br J Clin Pharmacol 2004; 58: 528–35.

34. Cheng JW, Kalis MM, Feifer S. Patient-reported adherence to guidelines of the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Pharmacotherapy 2001; 21: 828–41.

35. Choo PW, Rand CS, Inui TS, Lee ML, Ma CC, Platt R. A pharmacist-led intervention with HMG-CoA reductase inhibitors after acute myocardial infarction. Am J Health Syst Pharm 2005; 62: 1999–2010.

36. Chui MA, Deer M, Bennett SJ et al. Association between adherence to diuretic therapy and health care utilization in patients with heart failure. Pharmacotherapy 2003; 23: 326–32.

37. Conlin PR, Gerth WC, Fox J, Roehm JB, Bocuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001; 23: 1999–2010.

38. Coombs JH, Cornish L, Hiller P, Smith DG. Compliance and refill pattern behavior with HMG-CoA reductase inhibitors after acute myocardial infarction. Manag Care Interface 2002; 15: 54–8, 60.
Combination treatment.

- Evangelista LS, Dracup K. A closer look at compliance research. *J Hum Hypertens* 2002; 16: 439–44.
- Evangelista L, Degli Esposti L, Dracup K, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. *Clin Ther* 2002; 24: 1347–57; discussion 1344.
- Del Prato S, Volpe L. Rosiglitazone plus metformin: combination therapy for type 2 diabetes. *Expert Opin Pharmacother* 2004; 5: 1411–22.
- Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. *Manag Care* 2000; 9 (9 Suppl.): 2–6.

44. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence with antihypertensive drugs in new patients. *J Cardiovasc Nurs* 2002; 17: 834.

45. Doshi JA, Zuckerman IH, Picot SJ, Wright JT Jr, Hill-Westmoreland K. Compliance adherence and blood pressure control in patients with psychotropic disorders compared to persons without psychiatric illness. *Psychosomatics* 2005; 46: 135–41.

46. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. *Diabet Med* 2002; 19: 279–84.

47. Donnan PT, Steinke DT, Newton RW et al. Changes in treatment after the start of oral hypoglycaemic therapy in type 2 diabetes: a population-based study. *Diabet Med* 2002; 19: 606–10.

48. Dorn J, Naughton J, Taveras M, Turevski N. Correlates of compliance in a randomized exercise trial in myocardial infarction patients. *Med Sci Sports Exerc* 2001; 33: 1081–9.

49. Doshi JA, Zuckerman IH, Picot SJ, Wright JT Jr, Hill-Westmoreland AA. Adherence to prescribed oral antihypertensive and blood pressure control in patients with psychotropic disorders compared to persons without psychiatric illness. *Psychosomatics* 2005; 46: 135–41.

50. Dorn J, Naughton J, Taveras M, Turevski N. Correlates of compliance in a randomized exercise trial in myocardial infarction patients. *Med Sci Sports Exerc* 2001; 33: 1081–9.

51. Doshi JA, Zuckerman IH, Picot SJ, Wright JT Jr, Hill-Westmoreland AA. Adherence to prescribed oral antihypertensive and blood pressure control in patients with psychotropic disorders compared to persons without psychiatric illness. *Psychosomatics* 2005; 46: 135–41.

52. Dunbar-Jacob J, Bohachick P, Mortimer MK, Sereika SM, Foley M, Mortimer MK, Sereika SM, Foley M. Anticipated problems, compliance, and the outcome of hypertension treatment. *Pharm World Sci* 2001; 23: 60–4.

53. Evans JM, Donnan PT, Morris AD. Adherence to oral hypoglycaemic agents prior to insulin therapy in type 2 diabetes. *Diabet Med* 2002; 19: 685–8.

54. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. *Pharmacotherapy* 2000; 20: 410–6.

55. Feinbock C, Luger A, Klingsler A et al. Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. *Diabetes Nutr Metab* 2003; 16: 214–21.

56. Fonseca T, Clara JG. Polypharmacy and non-compliance in the hypertensive elderly patient. *Rev Port Cardiol* 2000; 19: 855–72.

57. Gascon JI, Sanchez-Onturino M, Ller B, Skidmore D, Saturno PJ. Treatment Compliance in Hypertension Study Group. Why hypertensive patients do not comply with the treatment: results from a qualitative study. *Fam Pract* 2004; 21: 125–30.

58. Girvin BG, Johnston GD. Comparison of the effects of a 7-day period of non-compliance on blood pressure control using three different antihypertensive agents. *J Hypertens* 2004; 22: 1409–14.

59. Goldman DP, Joyce GF, Escare JJ et al. Pharmacy benefits and the use of drugs by the chronically ill. *JAMA* 2004; 291: 2344–50.

60. Grant RW, Devita NG, Singer DE et al. Improving adherence and reducing medication discrepancies in patients with diabetes. *Ann Pharmacother* 2003; 37: 962–9.

61. Grant RW, O’Leary KM, Weibull JB, Singer DE, Meigs JB. Impact of concurrent medication use on statin adherence and refill persistence. *Arch Intern Med* 2004; 164: 2433–8.

62. Gregoire JP, Moisan J, Guibert R et al. Tolerability of antihypertensive drugs in a community-based setting. *Clin Ther* 2001; 23: 715–26.

63. Guthrie RM. The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: Results of the first myocardial infarction risk reduction program. *Clin Ther* 2001; 23: 970–80.

64. Hagstrom B, Mattsson B, Rost I-M, Gunnarsson RK. What happened to the prescriptions? A single, short, standardized telephone call may increase compliance. *Fam Pract* 2004; 21: 46–50.

65. Hamann GF, Weimar G, Glahn J, Busse O, Diener HC. Adherence to secondary stroke prevention strategies – results from the German Stroke Data Bank. *Cerebrovasc Dis* 2003; 15: 282–8.

66. Hamilton GA. Measuring adherence in a hypertension clinical trial. *Eur J Cardiovasc Nurs* 2003; 2: 219–28.

67. Harley CR, Williams S, McKonough KL, Nelson MA. Cholesterol management in a population of managed care enrollees. *J Clin Outcomes Manag* 2003; 10: 147–54.

68. Herman WH, Hoerger TJ, Brandle M et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. *Ann Intern Med* 2005; 142: 523–32.

69. Hernandez-Bonquillo L, Tellers-Zenteno JF, Garduno-Espinosa J et al. Factors associated with therapy noncompliance in type 2 diabetes patients. *Salud Publica Mex* 2003; 45: 191–7.

70. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. *Clin Ther* 2003; 25: 1064–73.

71. Hope CJ, Wu J, Tu W, Young J, Murray MD. Association of medication adherence, knowledge, and skills with emergency department visits by adults 50 years or older with congestive heart failure. *Am J Health Syst Pharm* 2004; 61: 2043–9.

72. Horvathova H, Kimlikova K, Balazovjech I, Kyselovic I. Compliance and the therapeutic effect in patients with arterial hypertension. *Bratisl Lek Listy* 2003; 104: 149–54.

73. Howell N, Trotter R, Mottram DR, Rowe D. Compliance with statins in primary care. *Pharmaceutical Journal* 2004; 272: 23–6.

74. Huser MA, Evans TS, Berger V. Medication adherence trends with statins. *Adv Ther* 2005; 22: 163–71.

75. Imbs JL, Nisse-Duragnet S, French Collaborative Candesartan Study Group. Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by home blood pressure in hypertensive patients. *Int J Clin Pract* 2005; 59: 78–84.
81 Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 462–7.
82 Jokisalo E, Kumpsalo E, Ehnlund H, Halonen P, Takala J. Factors related to non-compliance with antihypertensive drug therapy. J Hum Hypertens 2002; 16: 577–83.
83 Kalia NK, Miller LG, Nasir K, Blumenthal RS, Agrawal N, Budoff MJ. Visualizing coronary calcium is associated with improvements in adherence to statin therapy. Atherosclerosis 2006; 185: 194–9.
84 Khttab MS, Abosifoukh MA, Khan MY et al. Compliance and control of diabetes in a family practice setting. Saudi Arabia. East Mediterr Health J 1999; 5: 755–65.
85 Kilbourne AM, Reynolds CF 3rd, Good CB et al. How does depression influence diabetes medication adherence in older patients? Am J Geriatr Psychiatry 2003; 13: 202–10.
86 Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs 2000; 15: 90–6.
87 Kiotitsis DN, Giral P, Bruckert E, Turpin G. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther 2000; 25: 445–51.
88 Kogut SJ, Andrade SE, Willey C et al. Nonadherence as a predictor of antidiabetic drug therapy intensification (augmentation). Pharmacoepidemiol Drug Saf 2004; 13: 591–8.
89 Kopiar B, Sales AE, Pineros SL, Sun H, Li YF, Hedeen AN. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol 2003; 92: 1106–8.
90 Krapek K, King K, Warren SS et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother 2004; 38: 1357–62.
91 Kuo YF, Raji MA, Markides KS et al. Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican Americans over a 7-year period: data from the Hispanic established population for the epidemiologic study of the elderly. Diabetes Care 2003; 26: 3054–60.
92 Larsen J, Vachser A, Andersen M et al. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 2008; 49: 463–71.
93 Larsen J, Andersen M, Kragstrup J, Gram LF. High persistence of statin use in a Danish population: compliance study 1993–1998. Br J Clin Pharmacol 2002; 53: 375–8.
94 Lesaffre E, Kocmanova D, Lemos PA, Disco CM, Serruys PW. A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS. Clin Ther 2003; 25: 2431–41.
95 Lin EH, Katon W, Von Korff M et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care 2004; 27: 2154–60.
96 MacFadyen RJ, Gorski JC, Brater DC, Struthers AD. Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. Br J Clin Pharmacol 2004; 57: 622–31.
97 Maggini M, Raschetti R, Traversa G et al. The cerivastatin withdrawal crisis: a ‘post-mortem’ analysis. Health Policy 2004; 69: 151–7.
98 Mansur AP, Mattar AP, Tsuibo CE, Simao DT, Yoshi FR, Daci K. Prescription and adherence to statins of patients with coronary artery disease and hypercholesterolemia. Arq Bras Cardiol 2001; 76: 111–8.
99 Mar J, Rodriguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Hypertens 2001; 19: 149–55.
100 Melkian C, White TJ, Vanderplas A et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002; 24: 460–7.
Compliance in cardiovascular disease

133 Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. *Diabetes Care* 2002; 25: 1015–21.

134 Schoberberger R, Janda M, Pescosta W, Sonneck G. The COMpliance prAXIS survey (COMPASS): a multidimensional instrument to monitor compliance for patients on antihypertensive medication. *J Hum Hypertens* 2002; 16: 779–87.

135 Schultz JS, O'Donnell KC, McDoungish KL, Sasame R, Meyer J. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. *Ann J Manag Care* 2005; 11: 306–12.

136 Shalansky SJ, Levy AR. Effect of number of medications on cardiovascular therapy adherence. *Ann Pharmacother* 2002; 36: 1532–9.

137 Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. *Ann Pharmacother* 2004; 38: 1363–8, Epub 6 July 2004.

138 Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. *Am Heart J* 2003; 145: 438–44.

139 Spoelstra JA, Stolk RP, Heerdink ER et al. Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy. *Pharmacoeconomics* 2003; 12: 121–7.

140 Sturkenboom MCJM, Picelli G, Dieleman JP, Mazaffari E, Pompen M, van der Lei J. Association between adherence to antihypertensive treatment and goal attainment. *Milan*, Italy, 2005, June 17–21.

141 Sturkenboom MCJM, Picelli G, Dieleman JP, Mazaffari E, Pompen M, van der Lei J. Patient adherence and persistence with antihypertensive therapy: one-versus two-pill combinations. *Milan*, Italy, 2005, June 17–21.

142 Svensson S, Kjellgren KI, Ahlner J, Saljo R. Reasons for adherence with antihypertensive medication. *Int J Cardiol* 2000; 76: 157–63.

143 Takiya LN, Peterson AM, Finley RS. Meta-analysis of interventions for medication adherence to antihypertensive medications. *Ann Pharmacother* 2004; 38: 1617–24, Epub 10 August 2004.

144 Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlopidine besylate/benazepril HCl versus comparable component-based therapy. *Congest Heart Fail* 2003; 9: 324–32.

145 Tu W, Morris AB, Li J et al. Association between adherence measurements of metropolol and health care utilization in older patients with heart failure. *Clin Pharmacol Ther* 2003; 73: 189–20.

146 Turan B, Oes T, Molzan Turan J et al. The role of coping with disease in adherence to treatment regimen and disease control in type 1 and insulin treated type 2 diabetes mellitus. *Diabetes Metab* 2002; 28: 186–93.

147 Umans-Eckenhausen MA, Defesch JC, van Dam MJ, Kastelein JJ. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. *Arch Intern Med* 2003; 163: 65–8.

148 Valdez CA, Ulrich H. Similar medication compliance and control of dyslipidemia with simvastatin or atorvastatin in a staff-model HMO medical clinic. *J Manag Care Pharm* 2005; 11: 499–504.

149 Valuck RJ, Williams SA, MacArthur M et al. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. *Clin Ther* 2003; 25: 2936–57.

150 Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. *J Hypertens* 2004; 22: 1831–7.

151 Vanderpoel DR, Hussein MA, Watson-Heidari T et al. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. *Clin Ther* 2004; 26: 2066–75.

152 Wang PS, Benner JS, Glynn RJ, Winkelmayer WC, Mogun H, Avorn J. How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. *Pharmacoeconomics* 2004; 13: 11–9.

153 Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J. Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. *J Gen Intern Med* 2002; 17: 504–11.

154 Waunemacher AJ, Schepers GP, Townsend KA. Antihypertensive medication compliance in a Veterans Affairs Healthcare System. *Ann Pharmacother* 2002; 36: 986–91.

155 Wei L, Flynn R, Murray GD, MacDonald TM. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment? *Pharmacoeconomics Drug Saf* 2004; 13: 761–6.

156 Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. *Heart* 2002; 88: 229–33.

157 White TJ, Chang E, Leslie S et al. Patient adherence with HMG reductase inhibitor therapy among users of two types of prescription services. *J Manag Care Pharm* 2002; 8: 186–91.

158 Willey C, Redding C, Stafford J et al. Stages of change for adherence with medication regimens for chronic disease: development and validation of a measure. *Clin Ther* 2000; 22: 858–71.

159 Williams ML, Morris MT 2nd, Ahmad U, Yousef M, Li W, Ertel N. Racial differences in compliance with NCEP-III recommendations for secondary prevention at a Veterans Affairs medical center. *Etnh Dis* 2002; 12: 51–58–62.

160 Witham MD, Gillespie ND, Struthers AD. Tolerability of spironolactone in patients with chronic heart failure – a cautionary message. *Br J Clin Pharmacol* 2004; 58: 554–7.

161 Wogen J, Kreilick CA, Livornese RC, Yokoyama K, Frech F. Patient adherence with amlopidine, lisinopril, or valsartan therapy in a usual-care setting. *J Manag Care Pharm* 2003; 9: 424–9.